Calyxo, Inc.

Calyxo, Inc. is a medical device company specializing in minimally invasive urological surgery, with a focus on kidney stone management. The company manufactures the CVAC® System, an integrated ureteroscopic platform designed for complete stone clearance. The CVAC System combines multiple capabilities in a single device: laser lithotripsy, microjet irrigation, dynamic aspiration, and stone collection. The proprietary SURE Procedure (Steerable Ureteroscopic Renal Evacuation) is a treatment protocol performed exclusively with the CVAC System that uses laser lithotripsy, irrigation, and vacuum aspiration to achieve superior stone clearance outcomes. Clinical evidence from a randomized controlled trial demonstrates 97% stone clearance rates, superior to standard ureteroscopy. The company targets urology departments and ambulatory surgery centers performing endoscopic stone treatment. Calyxo positions the CVAC System as a game-changing innovation in kidney stone care, reducing procedural complexity by integrating multiple treatment modalities. The device appears to be FDA-cleared for clinical use (regulatory designation MAC00071.B referenced on homepage). The company is actively recruiting clinical staff and maintaining an active clinical development program with published outcome data.